Triple-negative breast cancer (TNBC) is an aggressive disease subtype that, unlike other subtypes, lacks an effective targeted therapy. Inhibitors of the insulin-like growth factor receptor (IGF1R) have been considered for use in treating TNBC. Here, we provide genetic evidence that IGF1R inhibition promotes development of Wnt1-mediated murine mammary tumors that offer a model of TNBC. We found that in a double transgenic mouse model carrying activated Wnt1 and mutant Igf1r, a reduction in IGF1R signaling reduced tumor latency and promoted more aggressive phenotypes. These tumors displayed a squamous phenotype with increased expression of keratins 5/6 and b-catenin. Notably, cell lineage analyses revealed an increase in basal (CD29 hi /CD24 þ ) and luminal (CD24 þ /CD61þ/CD29 lo ) progenitor cell populations, along with increased Nanog expression and decreased Elf5 expression. In these doubly transgenic mice, lung metastases developed with characteristics of the primary tumors, unlike MMTV-Wnt1 mice. Mechanistic investigations showed that pharmacologic inhibition of the IGF1R in vitro was sufficient to increase the tumorsphere-forming efficiency of MMTV-Wnt1 tumor cells. Tumors from doubly transgenic mice also exhibited an increase in the expression ratio of the IGF-II-sensitive, A isoform of the insulin receptor versus the IR-B isoform, which when stimulated in vitro resulted in enhanced expression of b-catenin. Overall, our results revealed that in Wnt-driven tumors, an attenuation of IGF1R signaling accelerates tumorigenesis and promotes more aggressive phenotypes with potential implications for understanding TNBC pathobiology and treatment. Cancer Res; 74(19); 5668-79. Ó2014 AACR.
Introduction
Triple-negative breast cancers (TNBC), classified as estrogen receptor-and progesterone receptor-negative and lacking HER2 amplification, remain the most challenging breast tumor subtype to treat due to their aggressive nature and the lack of effective treatment options. A number of recent studies have focused on identifying receptors and signaling pathways active in TNBCs; these studies and other molecular profiling analyses have revealed considerable heterogeneity within this breast cancer subtype; however, approximately 50% of TNBCs classify as basal-like (1) . Interestingly, several pathways with known roles in embryonic development and stem/progenitor cell self-renewal have been identified with critical roles in TNBCs including the Wnt/b-catenin, Notch, and Hedgehog pathways (for review see, ref. 2) . In this study, we used the MMTV-Wnt1 tumor mouse model, which forms tumors that predominantly express basal cell markers, are enriched for mammary stem and basal cell progenitors, and have transcriptomic characteristics similar to those arising in BRCA1 germline mutation carriers (3) (4) (5) .
The canonical Wnt pathway was first associated with mammary carcinogenesis when the Int1 integration site of the mouse mammary tumor virus (MMTV) was identified as a mammalian homolog of Drosophila Wingless polarity morphogen and was renamed Wnt1 (6). In subsequent experiments, Tsukamoto and colleagues further demonstrated that Wnt1 overexpression in mammary epithelium is sufficient to form tumors in mice (7) . An important intracellular response to secreted Wnt1 is the stabilization of b-catenin, which can enter the nucleus and transactivate Wnt target genes. The stabilization of b-catenin is a hallmark of canonical Wnt signaling, which is enhanced in human basal-like breast cancers (8) . A recent study further demonstrated an association of Wnt signaling with lung and brain metastases in patients with TNBC (9) .
Recent data suggest that the insulin-like growth factor (IGF) signaling axis also has a role in TNBC. IGF gene signatures are increased in TNBCs and TNBC cell lines and IGF signaling promotes proliferation and survival of TNBC cells (10, 11) . The IGF signaling system consists of two ligands, IGF-I and IGF-II, which can activate several receptor subtypes. Both ligands have high affinity for the IGF type I receptor (IGF1R), which has been implicated in several types of cancer including prostate, colon, and breast (12, 13) . Results from early studies demonstrated that the IGF1R is necessary for transformation of fibroblasts by a variety of oncogenes (for review, see ref. 14) . Subsequent studies demonstrated that either overexpression or constitutive activation of the IGF1R in mammary epithelium results in hyperplasia and development of tumors (15, 16) . In addition to the IGF1R, IGF-II also can signal through the A isoform of the insulin receptor (IR-A), a splice variant of the IR that lacks exon 11. IGF-II signaling through the IR-A is important in embryonic development (17) and this signaling loop is also prevalent in a variety of cancers (18) (19) (20) . The ratio of IR-A: IR-B is higher in breast cancer cell lines and in primary breast tumors than in normal tissue (19, 21) . Compared with the IR-B isoform, which is the more common metabolic form of the IR found on insulin-sensitive cells, the IR-A functions in cell growth, proliferation, and survival (For review, see ref. 22 ). Interestingly, phosphorylation and total levels of IR (but not IGF1R) have been correlated with poor survival in patients with invasive breast cancer of all subtypes (23) . These studies highlight the complexity of IGF signaling and the need for a better understanding of how it functions in the context of oncogene pathways.
Here, we tested the function of the IGF1R in MMTV-Wnt1-mediated mammary tumorigenesis by coexpressing a kinase-dead Igf1r transgene under the control of the MMTV promoter. We demonstrate the attenuation of IGF1R in combination with Wnt1 overexpression decreases mammary tumor latency and incidence, increases the basal cell and aggressive phenotype of the tumors, and leads to lung metastases. Similarly, acute pharmacologic inhibition of the IGF1R is sufficient to increase tumorsphere formation in vitro. We further demonstrate that the reduction in IGF1R signaling in the MMTV-Wnt1 tumor model enhances an IGF-II/IR-A signaling loop and canonical Wnt signaling.
Materials and Methods

Transgenic mouse lines
All animal protocols were approved by Rutgers University [formerly University of Medicine and Dentistry of New Jersey (UMDNJ), Newark, NJ] Institutional Animal Care and Use Committees. All experiments were managed in accord with the NIH guidelines for the care and use of laboratory animals. The MMTV-dominant-negative Igf1r (dnIgf1r) transgenic mouse line was established by pronuclear injections into FVB embryos. The MMTV-LTR promoter and the kinasedead human Igf1r used for the transgenic construct were described previously (24) (25) (26) . Three independent transgenic lines were obtained that were used to verify transgene expression and initial phenotype. For developmental analysis, hemizygous or homozygous males and females were mated to obtain transgenic or wild-type females for experiments. For flow cytometry, FBV age-matched wild-type females were used as controls. The MMTV-Wnt1 line on an FVB background [FVB.Cg-Tg(Wnt1)1Hev/J] was obtained from Jackson Laboratories. The MMTV-Wnt1//MMTVdnIgf1r (bigenic) line was obtained by crossing a MMTVWnt1 hemizygous male with a MMTV-dnIgf1r homozygous female. Female littermates (bigenic vs. MMTV-Wnt1) were used for experiments. Animal care was provided by the veterinary staff of the Division of Animal Resources in the New Jersey Medical School Cancer Center of Rutgers Biomedical Health Sciences (Newark, NJ). MMTV-Wnt1 and bigenic female mice were palpated every 5 days for tumors beginning at 3 weeks of age; tumors were harvested when they reached 1 cm.
Mammary epithelial cell purification, flow cytometry, and cell culture Primary mammary epithelial cells (MEC) were purified from nonmalignant, premalignant, and malignant mammary glands as described previously, except tumor cells were enzymatically digested for 2.5 hours (27) . For mammary cell sorting, single MEC suspensions from nonmalignant and premalignant tissue were obtained from the thoracic and inguinal mammary glands (28, 29) .
Cytometric analysis of cells immunolabeled with fluorochrome-conjugated surface labeling and/or intracellular labeling was performed as described (28) . Hematopoietic lineage markers (phycoerythrin-conjugated anti-mouse CD45, CD140a, Gr-1, TER119, CD31, and CD11c; Biolegend) were used to exclude stromal and hematopoietic cell contamination (lineage minus, Lin À ). Acquisition and analysis of cell-associated fluorescence were performed using a BD FACSCalibur cytometer or LSR and TreeStar Inc. FlowJo software, respectively.
For FACS, antibodies and mammary epithelial single cells were resuspended at 10 6 cells/mL in PBS with 2% BSA and 2% goat serum (FACS buffer). Cells were immunolabeled with fluorochrome-conjugated anti-CD29 Alexa Fluor 647 (1:280, Biolegend), CD24 Alexa Fluor 488 (1:250, Biolegend), and CD61 Biotin (1:200, BD Pharmingen). Single cells were prepared for FACS, as described previously (30) . Cells were sorted at 70 psi using a 70-mm nozzle on the Becton Dickinson FACS Vantage.
The sphere limiting dilution assay (SLDA) was performed, as described previously (31) . SLDA experiments for tumorspheres utilized the functional blocking antibody, IMC-A12 (15 mg/mL), a monoclonal antibody against IGF1R (provided by ImClone Systems, a wholly owned subsidiary of Eli Lilly and Co).
For signaling experiments, mammary organoids were isolated and treated with 50 nmol/L of IGF1 for 15 minutes at 37 C and then harvested for Western blot or real-time (RT)-PCR analysis as described previously (32, 33) . 
RNA isolation and quantitative real-time PCR
Freshly isolated nonmalignant, premalignant, and tumor samples were used for RNA extraction with TRIzol (Gibco) according to manufacturer's instructions. For RT-PCR, total RNA (500 ng) from Universal mouse reference RNA (Stratagene) and primary cells (normal and tumor mammary tissue) were reverse transcribed, as described previously (32) . Samples were run in triplicate and results were analyzed on ABI 7400 software. b-Actin was used as the endogenous control. Mouse primers for Twist1, Nanog, Hey1, DLL4, Elf-5, and human IGF1R were from Quantitect. The primers used to analyze IR-A and IR-B were described previously (32) .
Histology and immunohistochemistry
Tissue samples were drop-fixed in 3% paraformaldehyde for 6 hours and embedded in paraffin and sectioned at 10 mm. Primary tumor and lung sections were used for hematoxylin and eosin (H&E) staining or further processed for antigen retrieval and immunofluorescence as described previously (33) . Primary antibodies included cytokeratin 5, (1:200, Covance), b-catenin (1:200, Santa Cruz Biotechnology), and cytokeratin 6 (1:1,000, Covance). Lung metastases were counted in three H&E-stained sections per lung, 80 mm apart by an investigator blinded to genotype (n ¼ 4).
Protein isolation and Western immunoblotting
Total protein was isolated and used for Western immunoblotting as described previously (32) using antibodies to b-catenin (1:1,000; Santa Cruz Biotechnology), P-Akt (Ser473; 3787), Akt (9272), P-Erk 1/2 (Thr 202 and Tyr 204), and total Erk (1:1,000, all from Cell Signaling Technology). b-Actin (1:5,000; Sigma) was used as an endogenous control.
Statistical analyses
Statistical differences for RT-PCR, Western immunoblotting, and flow cytometry analyses were determined using Student t test for two-group comparisons. P values < 0.05 were used to represent significance. All results were reproduced across multiple experiments. Statistical significance for the Kaplan-Meier data was determined using a Mantel-Cox test and GraphPad software.
Results and Discussion
Attenuated IGF1R signaling in the MMTV-Wnt1 mammary tumor model decreases tumor latency and increases tumor multiplicity
To investigate the role of IGF1R signaling in Wnt1-mediated mammary tumorigenesis, we established a bitransgenic (bigenic) mouse line carrying a kinase-dead, dominant-negative Igf1r transgene driven by the MMTV promoter (MMTVdnIgf1r) and a MMTV-Wnt1 transgene. Nulliparous bigenic female mice developed mammary tumors with decreased latency compared with the MMTV-Wnt1 female mice (Fig.  1A) . MMTV-Wnt1-expressing mice had a mean latency consistent with previous results (37, 38) . No mammary tumors were detected in mice carrying only the MMTV-dnIgf1r transgene up to 1 year. The bigenic mice also showed increased tumor multiplicity; 12 of 16 bigenic females developed more than 1 tumor, whereas only 1 of 13 MMTV-Wnt1 females developed more than one tumor (Fig. 1B) . Growth rates of tumors measured from time of palpation to harvest were similar between the MMTV-Wnt1 and bigenic strains (Fig. 1C) .
Histopathology of the mammary tumors revealed an increase in squamous and pillar cells in the bigenic tumors compared with MMTV-Wnt1 mammary tumors ( Fig. 1D and E). A similar increase of squamous differentiation was shown previously in a mouse line expressing a stabilized b-catenin transgene (DE3 b-catenin; refs. 39, 40) . The bigenic tumors showed increased staining for both cytokeratin 5 (K5) and b-catenin ( Fig. 1F and G). Expression of cytokeratin 6 (K6), a marker of mammary biopotential progenitor cells (41) and expressed in MMTV-Wnt1 tumors (42), was also more prevalent in the bigenic tumors compared with MMTV-Wnt1 tumors ( Fig. 1H and I ). Increased expression of K6 was also observed in the DE3 b-catenin tumors where it was used as a marker of squamous differentiation (40) . These data suggest that decreased IGF1R signaling accelerates tumor initiation and alters tumor characteristics toward a more basal and squamous phenotype in the context of elevated Wnt signaling.
Loss of IGF1R during normal mammary development increases luminal progenitors and decreases stem/ myoepithelial lineages IGF1R signaling functions in proliferation and survival in a variety of cell types and has been recognized as a promoter of tumorigenesis when overexpressed in multiple tissues, including mammary epithelium. However, our findings suggest the attenuation of the IGF1R in vivo has the opposite effect in the context of high Wnt signaling. These unexpected results suggested the possibility that the expression of the dnIgf1r transgene may have altered normal mammary epithelial development making it more susceptible to Wnt1 tumor initiation. To test this hypothesis, we examined the effect of the MMTV-dnIgf1r transgene on normal epithelial cell populations in early development in the absence of Wnt1 expression. Morphologic analyses of the MMTV-dnIgf1r glands by whole mount staining revealed a reduction in tertiary branching in post-pubertal glands ( Fig. 2A-D) . Expression of the dnIgf1r transgene was verified using primers to the human Igf1r (Fig. 2E) . To confirm that IGF signaling was reduced in MECs of the MMTVdnIgf1r transgenic line, we treated isolated primary mammary organoids with IGF-I to stimulate IGF1R signaling. IGF-I stimulation in the wild-type MECs led to increased levels of P-Akt and P-Erk1/2 as expected (P < 0.001); however, levels of P-Akt and P-Erk1/2 were reduced in MECs from MMTV-dnIgf1r glands (P 0.02; Fig. 2F and G).
The reduction in tertiary branching of glands derived from the MMTV-dnIgf1r mice, suggested the possibility that the reduction in IGF signaling had altered proliferation and or differentiation in specific epithelial cell lineages (43) . We previously showed that the expression of the MMTV-dnIgf1r reduced mammosphere, forming potential in a SLDA in vitro, suggesting a reduction in the basal cell lineage (31) . To directly analyze lineage alterations, we isolated MECs from MMTVdnIgf1r and wild-type glands and analyzed the expression of lineage-specific markers by flow cytometry, using antibodies to the cell surface markers CD24 (heat shock antigen) and CD29 (b1 integrin) that distinguish luminal (CD24 The results of the flow cytometry analyses support the hypothesis that a shift in cell lineage may be responsible for the hypobranching phenotype as well as the enhanced Wnt tumor susceptibility in the MMTV-dnIgf1r glands. Macias and colleagues showed that a reduction in basal cells reduces the numbers of lateral branches (43) . Importantly, several studies demonstrate that mammary progenitor cells are the targets of oncogenesis by the Wnt pathway (42, 45, 46) including a luminal progenitor population (46) . Thus, expansion of the luminal progenitor population due to a reduction in IGF signaling may lead to increased susceptibility to Wnt-mediated transformation. In support of this is the finding that luminal progenitors are the likely targets for transformation in BRCA1 tumors (47) .
On the basis of the developmental and lineage alterations in the MMTV-dnIgf1r glands, we hypothesized that defective IGF signaling may have enhanced another signaling pathway responsible for luminal progenitor expansion. A likely candidate for this is the Notch signaling pathway; constitutive activation of Notch signaling promotes expansion of undifferentiated CD61
þ CD29lo luminal progenitors (48) . Moreover, Notch signaling is necessary for Wnt1-mediated tumorigenesis in human mammary epithelial cells (49) . Expression of the Notch target gene Hey1 and the Notch ligand gene Dll4 were increased in primary MECs from MMTV-dnIgf1r glands (P 0.05; Fig. 2L and M) . Taken together, our findings support the hypothesis that the increased numbers of luminal progenitors and susceptibility to Wnt-mediated tumors may be due to dysregulation of Notch signaling in the dnIgf1r epithelium.
Increased Notch signaling in dnIgf1r/Wnt1 hyperplasia Because we observed a disruption in lineage distribution in the MMTV-dnIgf1r mammary epithelium, we analyzed premalignant epithelium to determine whether the myoepithelial to luminal progenitor lineage shift persisted in hyperplasia of the bigenic glands. We isolated tumor-free, preneoplastic glands contralateral to glands containing tumors. As most tumors developed at an earlier time in the bigenic mice versus the MMTV-Wnt1 mice, the hyperplastic epithelium was stage- Mouse universal cDNA (Msþ) was used as a negative control. F and G, graphs showing levels of P-Akt/total Akt (F) or P-Erk/total Erk (G) following acute stimulation of purified mammary epithelial spheroids with IGF-I. Western immunoblotting was performed on protein isolated from epithelial preparations from each genotype (n ¼ 3). Ã , P < 0.001 vs. control; ÃÃ , P 0.01 vs. WT. H and I, flow cytometry using mammary lineage markers CD29 APC, CD24 FITC, and excluding lineage markers (CD45, CD31, CD11b, Gr-1, Ter119) of purified MECs from WT and MMTV-dnIgf1r glands at 11 weeks. CD24 þ CD29 hi in MMTV-dnIgf1r versus WT: P < 0.001; CD24 þ CD29lo in MMTV-dnIgf1r versus Wt; P < 0.001. J and K, flow cytometry using CD24 þ CD29lo CD61 þ lin À cell markers for the identification of the luminal progenitor (Fig. 3A-D) . As mammary tumors developed as early as 7 to 8 weeks in the bigenic mice, we analyzed age-matched glands at 5 weeks from both genotypes, a time when both lines were tumor-free. Bigenic and MMTV-Wnt1 glands at 5 weeks were both hyperplastic and showed no distinct morphologic differences ( Fig. 3E and F) . Although the MMTV-Wnt1 tumors have a predominant basal phenotype, they also contain a population of luminal-type cells with some expression of ER and PR (5, 50). Thus, we measured RNA expression of progesterone receptor (PR) and RANKL in MMTV-Wnt1 compared with bigenic hyperplasia in luminal epithelial fraction after FACS. PR and RANKL expression were unchanged between the two tumor types (data not shown).
Despite the absence of cell lineage changes, morphologic alterations, or hormone receptor status and signaling, the bigenic hyperplasia had a significant increase in expression of the Notch target gene, Hey1, (P 0.05; Fig. 3G ). The increase in Notch signaling in bigenic hyperplasia despite no difference in the size of the progenitor populations suggests an amplification of Notch signaling in individual progenitor cells. The lack of detectable amplification of the luminal progenitor population in the bigenic versus MMTV-Wnt1 hyperplasia may be due to the ability of the Wnt pathway alone to amplify this population. These data suggest that the increase in Notch signaling that persists in the bigenic hyperplasia may expedite tumor formation.
Disruption of the IGF1R in the MMTV-Wnt1 tumor model enhances the basal tumor phenotype and increases the luminal progenitor population Although there were no obvious morphologic or lineage differences in the hyperplasia, there were clear morphologic differences in the bigenic versus MMTV-Wnt1 tumors (Fig. 1) . When we analyzed the tumor cell populations by flow cytometry, we found that the bigenic tumors had an increase in the basal cell population (P < 0.001) and a decrease in the luminal cell population (P < 0.001; Fig. 4A and B) . Furthermore, we found an increase in the CD61 þ CD24 þ CD29 lo luminal progenitor population in the bigenic tumors compared with the Wnt1 tumors (P ¼ 0.01; Fig. 4C and D) . Interestingly, this population was previously described as the putative tumorinitiating population in an MMTV-Wnt1 mammary tumor model (46, 51) , initially shown by Li and colleagues (42) . These results suggest a shift towards a more basal tumor phenotype in MMTV-Wnt1 tumors in the presence of the dnIGF1R transgene. Similar to analysis of the hyperplasia, PR and ER expression were unchanged in the MMTV-Wnt1 compared with the bigenic tumors (data not shown).
We further analyzed the MMTV-Wnt1 and bigenic tumors for changes in expression of markers of differentiation and epithelial-to-mesenchymal transition (EMT). Elf5, which has known roles in alveologenesis as well as in mammary stem and progenitor cell fate (52) , was decreased in bigenic tumors compared with MMTV-Wnt1 tumors (P 0.05, Fig. 4E ). Targeted deletion of Elf5 in mice leads to an accumulation of undifferentiated luminal and basal progenitors (53) , and loss of Elf5 leads to an increase in the CD61 þ luminal progenitors and hyperactive Notch signaling (52, 53) . Finally, conditional knockouts of Elf5 in the MMTV-Neu tumor model showed that Elf-5 represses markers of EMT (53) .
As the bigenic tumors showed an increase in the basal cell population that would confound interpretation of alterations in expression of EMT genes, we isolated RNA from FACS-sorted basal and luminal populations, from bigenic versus MMTVWnt1 tumors. Expression of Twist1 and Nanog, genes that are upregulated in EMT (54) , was increased in the bigenic tumor basal population; the increase in Nanog expression was statistically significant (P 0.05, Fig. 4F ). Elevation of Twist1 approached statistical significance (P ¼ 0.06, data not shown). Expression of these genes was unaltered in the luminal cell population (data not shown). Collectively, these data suggest that loss of IGF1R signaling in the presence of an overexpression of the Wnt1 oncogene enhances the basal phenotype of the resulting tumor and increases the putative metastatic potential by attenuating Elf5 expression and increasing EMT mediators.
Increased lung metastases in bigenic mice
The more aggressive tumor phenotype in the bigenic mice suggested the possibility that they might more readily contribute to lung metastases. Typically MMTV-Wnt1 tumors, although basal-like, are not highly metastatic and produce 
progenitors (P 0.01). n ¼ 5 independent sorts for A-D. E and F, changes in Elf5 (E) and Nanog (F) expression between MMTV-Wnt1 versus bigenic tumors were determined by RT-PCR. Elf5,few lung metastasis (7). The bigenic mice had detectable lung metastases ( Fig. 5A and B; 3.4 mets/lung), whereas the MMTVWnt1 mice had no detectable metastases at the time of primary tumor removal (n ¼ 4/genotype). Consistent with expression of K5 and K6 in the primary bigenic tumors, bigenic lung metastases also showed K5 and K6 expression (Fig. 5C-F) . K5 staining appeared also in basal layers around some alveoli in the lungs from both genotypes as well as wild-type lungs (not shown). However, no K5 was seen in other areas of the MMTVWnt1 lungs and we observed no detectable K6 staining in either the MMTV-Wnt1 or wild-type lungs. The K6 staining was absent from the smaller metastases (Fig. 5E ) but was prevalent in large lung metastases of the bigenic animals ( Fig. 5F ), suggesting that the primary tumor cells express K6 after transdifferentiation to a squamous phenotype.
Pharmacological inhibition of IGF1R signaling in Wnt1 primary tumor cells in vitro increases tumorsphere formation We hypothesized that the alteration in phenotype of the bigenic tumors could be due to ongoing expression of the dnIGF1R transgene. Analysis of the bigenic hyperplasia and tumors showed transgene expression equivalent to the expression in the MMTV-dnIGF1R glands in the absence of the MMTVWnt1 transgene (Fig. 2E) . To test whether acutely inhibiting IGF1R in primary MMTV-Wnt1 tumor cells in vitro leads to a more aggressive growth phenotype, we treated MMTV-Wnt1 tumor cells with an IGF1R blocking antibody in a SLDA (31, 55) . When IGF1R signaling was inhibited with a blocking antibody (A12), we observed an increase in frequency of tumorsphere formation by the MMTV-Wnt1 tumor cells from 1 in 101 to 1 in 24 (Fig. 6A) . Moreover, we sorted primary MMTV-Wnt1 tumor cells using basal and luminal lineage cell markers and measured sphere-forming frequency in both luminal and basal MMTV-Wnt1 tumor cells in tertiary spheres plus or minus the IGF1R blocking antibody. As expected, the basal cell population showed a greater tumor-initiating frequency in the absence of IGF1R inhibition and C). Interestingly, IGF1R inhibition altered the tumorsphere-forming potential of the luminal cells to a level similar to that of the basal population. Studies using an MMTV-Neu mouse model have demonstrated that the frequency of tumorsphere formation strongly correlates to the number of TICs in a given population (56, 57) . TIC potential does not necessarily correlate to the cell of origin, but rather is an indication of the ability of a cell to self-renew and initiate tumorigenesis (55) . Thus, the increase in tumorsphere growth by the MMTV-Wnt1 tumor cells with IGF1R inhibition suggests that attenuating IGF1R signaling enhances the TIC population of MMTV-Wnt1 tumors.
Attenuation of the IGF1R in MMTV-Wnt1 mammary epithelium increases IR A:IR-B expression and canonical Wnt signaling
We observed a decrease in tumor latency, enhanced basal phenotype, and squamous cell transdifferentiation in the bigenic mice. In addition, tumorsphere-forming frequency of MMTV-Wnt1 tumor cells increased when IGF1R signaling was attenuated in vitro. Taken together, these findings suggest that the canonical Wnt pathway may be enhanced in the absence of IGF signaling. Consistent with this hypothesis, protein levels of b-catenin, normally stabilized by activation of canonical Wnt signaling, were increased in the bigenic tumors versus Wnt1 tumor cells (Fig. 7A) .
Downregulation of IGF1R signaling in a variety of breast cancer cell lines increases insulin sensitivity by increasing cell surface expression of holo-IR because of a reduction in hybrid IR/IGF1R cell surface expression (58) . Moreover, MMTV-Wnt1 tumors are responsive to diet-induced obesity as well as caloric restriction, suggesting insulin has a role in MMTV-Wnt1 tumor growth (59) . We hypothesized that the reduction of IGF1R in the context of Wnt1 signaling may have led to an alteration in IR signaling. When we determined the expression of IR isoforms IR-A and IR-B, we saw a significant increase in the IR-A:IR-B ratio in the bigenic tumors (P < 0.01, Fig. 7B ). The increase in the ratio of IR-A to IR-B was due predominantly to a decrease in IR-B expression, consistent with findings in other tumors (21, 60) . To determine whether the increase in IR-A:IR-B occurred before tumor onset, we determined the expression of the IR isoforms in the FACS-sorted luminal hyperplasia population (CD24 þ   CD29 lo ), as the luminal population accounted for the majority of the hyperplastic epithelium. We found that the IR-A:IR-B ratio was significantly enhanced in the bigenic luminal hyperplasia despite no change in cell lineage distribution (P < 0.002, Fig. 7C ). The early shift in IR isoforms suggests a potential role for IR-A in Wnt1 tumor initiation. Finally, we also measured phosphorylation and expression levels of insulin receptor substrate 1 (IRS-1) in MMTV-Wnt1 and bigenic tumors. Downregulation of IGF1R and IRS-1 correlates with breast tumor progression, and their levels are inversely correlated with high proliferation rates and dedifferentiated breast cancers (61) . Furthermore, in prostate cancer, an increase in the IR-A:IR-B ratio is positively correlated with a decrease in IRS-1 expression (62) . Consistent with the increase in the IR-A:IR-B ratio in the bigenic tumors, the level of P-IRS-1 was decreased in the bigenic tumors (P ¼ 0.05, Fig. 7D ). Interestingly, total IRS-1 was unaltered in the bigenic tumors.
The increased ratio of IR-A:IR-B indicates that the bigenic tumors will respond differently to circulating insulin based on the mitogenic/growth properties of the IR-A isoform. However, IGF-II also binds the IR-A with high affinity, and activation of IGF-II/IR-A signaling is prevalent in a variety of cancers (18) (19) (20) . Interestingly, expression of IGF-II was significantly higher in the bigenic tumors (P ¼ 0.05, Fig.  7E ). The increase in IGF-II expression is consistent with the increase in the CD61 þ luminal progenitors, as they are These data show that reduction of IGF1R signaling in the mammary epithelium in a MMTV-Wnt1 tumor leads to an increase in the canonical Wnt signaling target, b-catenin, and enhances the IR-A:IR-B ratio known to be elevated in many breast cancers. The stabilization of b-catenin has been shown previously to increase squamous transdifferentiation in MMTV-Wnt1 tumors (40) . The increase in b-catenin in the bigenic tumors suggests that loss of IGF1R signaling helps stabilize b-catenin levels and thus enhances the MMTV-Wnt1 tumor phenotype, driving the resulting tumors towards a more squamous and basal cell phenotype.
Conclusions
These data show that disruption and attenuation of the IGF1R during pubertal growth of the mammary gland alters cell lineage distribution, which may also alter susceptibility to oncogenic transformation. In our model, we observed a decrease in tumor latency in the bigenic mouse model compared with MMTV-Wnt1 mice. The resulting tumors were more basal and had increased expression of EMT markers, suggesting the tumors had a more aggressive phenotype. The attenuation of the IGF1R in the MMTV-Wnt1 tumors led to an increase in Notch targets as well as the IR-A:IR-B ratio. The increase in Notch signaling suggests that the IGF1R may play a role either directly or indirectly in regulating Notch signaling. Taken together, the results suggest that IGF1R and IR-A signaling have inverse roles in MMTV-Wnt1 oncogenesis and that inhibiting the IGF1R increases signaling through the IR-A and, subsequently, enhances canonical Wnt signaling. 
